Company Information
CIN
Status
Date of Incorporation
22 June 1982
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
27 September 2023
Paid Up Capital
13,924,280
Authorised Capital
80,000,000
Directors
Hitesh Kiran Kumar
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Pravin Keshrimal Jain
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Abhay Uttamchand Jain
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Uttamchand Kesharimal Jain
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Ashokkumar Keshrimal Jain
Director/Designated Partner
about 8 years ago
about 8 years ago
Past Directors
Kishor Champalal Solanki
Additional Director
over 10 years ago
over 10 years ago
Usha Kishor Jain
Additional Director
over 10 years ago
over 10 years ago
Rahul Ashokkumar Jain
Additional Director
almost 19 years ago
almost 19 years ago
Babulal Kesharimal Jain
Managing Director
over 43 years ago
over 43 years ago
Patents
The invention discloses a process for preparation of highly pure dialkyl pemetrexed by reacting a 2-(4-hydroxy-6-aminopyrrolo(2,3-d)pyrimidin-3-y])ethylbenzoic acid with a glutamatic acid diester or its salt in presence of a safe, mild, inexpensive, non-oxidative and easy to handle reagent such as substituted triphe...
Disclosed herein is a freeze dried composition of atracurium besylate comprising atracurium besylate; an acid to adjust the pH and a co-solvent along with water as a principle solvent.
Disclosed herein is stable freeze dried composition of atracurium besylate which comprises atracurium besylate; an acid to adjust the pH and polyvinyl Pyrolidone.
The invention discloses a novel process for highly chemoselective reactions of substituted anilines without any detectable reaction at aromatic amino group. The invention also relates to a novel process for preparation of neostigmine methylsulphate via chemoselective reaction of 3-amionphenol and aryl dimethylcarbam...
The present invention discloses stable aqueous Injectable suspension comprising Betamethasone Sodium Phosphate and Betamethasone Dipropionate in easily re-dispersible form.
The invention discloses a novel method for preparing neuromuscular blocking agents using aryl esters as a reagent of di-acylation as well as highly regioselective mono-acylation of androstane-diols.
The invention discloses a novel process for quaternization of (2β,3α,5α, 16β, 17β)-2,16-bispiperidino-3,17-diacetoxy-5-androstane with methyl bromide in presence of a cyclic ether. The invention further discloses purification of quaternary salt to provide highly pure vecuronium bromide with unspecified impurity leve...
The invention discloses compositions of clear injectable solution which comprises Midazolam, pentazocine, tonicity agent, chelating agent, and acids to adjust pH.
The invention discloses a process for enantiomeric enrichment of 2",6"-pipecoloxylidide using a chiral carbamoyl benzoic acid to provide (S)-enantiomer in high yield and high enantiomeric purity. The invention also discloses novel intermediates formed in the process of enantiomeric enrichment of 2",6"-pipecoloxyIidi...
The invention discloses a novel process for preparation of succinylcholine chloride via transesterification of succinic acid diester with choline chloride.
The present invention discloses solid oral formulation of etoposide, i.e. 4'-demethylepipodophillotoxin-9-(4,6-O-ethylidene-p-D-glucopyranoside ), comprising free flowing granules of Etoposide in hard gelatin capsules with good oral bioavailability.
The invention discloses a one-pot economical process for preparation of highly pure 6-[(l-methyl-4-nitro-lH-imidazol-5-yl)thio]-lH-purine by reacting 6-mercaptopurine with 5-halo-l-methyl-4-nitro-lH-imidazole in presence of a base in aqueous medium.
Disclosed herein is a stable aqueous injectable pharmaceutical composition comprising Diclofenac sodium as an active ingredient in an amount of 2.5% to 2.625%, a chelating agent in an amount of 0.01% 0.02% and other pharmaceutically acceptable excipients, wherein the said formulation is free of propylene glycol.
...
Disclosed herein is a stable aqueous injectable pharmaceutical composition of 75mg of Diclofenac Sodium in I ml solution having viscosity of 0.5 to 1.5 mm2 / sec, wherein said composition is characterized by comprising a single co-solvent/solubilizer in an amount of 20 to 60% and water as principle solvent.
...
The invention discloses a novel process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate via formation of aryl dimethylcarbamate which can be easily obtained from diaryl carbonate and dimethylamine.
The invention discloses a process for preparation of (dl)-norepinephrine salt by reacting 3,4-dihydroxy-a-haloacetophenone with hexamethylenetetramine to provide hexamine salt; followed by hydrolysis and hydrogenation. The invention also discloses a novel intermediate formed in the process and its synthesis.
...
The invention discloses a novel process for preparation of dexmedetomidine in higher yield and with enantiomeric purity more than 99%.
The present invention discloses a pharmaceutical composition comprising non-sticky, free flowable, dried granules of essential phospholipid as active ingredient along with pharmaceutically acceptable excipients encapsulated into hard gelatin capsules and to the process of preparation thereof.
A highly stabilized, economic and less viscous (after reconstitution), lyophilized injectable composition of Lorazepam is disclosed. The composition of the present invention is very stable for longer period at room temperature with optimum bioavailability and desirable pharmaceutical properties.
...
This invention discloses new stable lyophilized preparations of Cyclophosphamide for injection with excellent storage stability, less reconstitution time and to a process for their preparation. The invention further discloses Cyclophosphamide for injection obtained by reconstitution of the lyophilized products descr...
Disclosed herein are free flowable, nonsticky essential phospholipid granules with optimum stability, good compressibility suitable for preparation of solid oral tablet formulation. The formulation comprises essential phospholipid derived from soya lecithin as an active ingredient preferably with Adsorbent, Binder, ...
The present invention discloses an improved process for preparation of highly pure cyclopentyl mandelic acid derivative of formula (I), an intermediate of glycopyrrolate, without using hazardous chemicals.
The present invention discloses an improved process for preparation of substantially pure pentamethylene bis(1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxy-1H-isoquinoline-2-propionate), a compound of formula I and its acid addition salts in good yields. Pentamethylene bis(1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-...
Registered Trademarks
[Class : 5] Pharmaceutical And Medicinal Preparations In Class 5
[Class : 5] Pharmaceutical And Medicinal Preparation
[Class : 5] Pharmaceuticals, Medical And Veterinary
Preparations; Dietetic Food And Substances Adapted For Medical Or
Veterinary Use
View +981 more Brands for Neon Laboratories Limited.
Charges
23 August 2018
The Federal Bank Ltd
15 Lak
24 July 2018
The Federal Bank Ltd
56 Lak
23 February 2018
Standard Chartered Bank
3 Crore
21 August 2017
Bassein Catholic Co-operative Bank Limited
5 Crore
11 August 2017
Dcb Bank Limited
5 Crore
28 April 2017
Bassein Catholic Co-operative Bank Limited
2 Crore
31 March 2017
Bassein Catholic Co-operative Bank Limited
96 Lak
07 April 2016
Dcb Bank Limited
7 Crore
10 April 2015
State Bank Of India
500 Crore
04 December 2014
State Bank Of India
136 Crore
30 May 2014
Bassein Catholic Co-operative Bank Limited
6 Crore
28 February 2014
Dcb Bank Limited
4 Crore
22 February 2013
State Bank Of India
12 Lak
31 May 2012
Development Credit Bank Limited
2 Crore
02 March 2002
Sicom Ltd
2 Crore
27 August 1997
State Bank Of India
120 Crore
31 March 1994
Maharashtra State Financial Corproation
35 Lak
20 December 1991
State Bank Of India
40 Lak
17 October 1988
State Bank Of India
43 Lak
17 October 1988
State Bank Of India
43 Lak
07 October 1988
State Bank Of India
43 Lak
02 January 1986
State Bank Of India
34 Lak
30 March 1984
The Maharashtra State Financial Corporation
20 Lak
07 February 2017
Tata Capital Financial Services Limited
7 Crore
26 September 2014
Tata Capital Financial Services Limited
10 Crore
19 December 2012
State Bank Of India
5 Lak
10 June 2013
State Bank Of India
9 Lak
22 February 2013
State Bank Of India
11 Lak
19 December 2012
State Bank Of India
6 Lak
21 October 2011
Development Credit Bank Limited
5 Crore
30 August 2023
State Bank Of India
0
14 October 2021
Standard Chartered Bank
0
06 October 2021
State Bank Of India
0
24 July 2018
Others
0
28 April 2017
Others
0
23 February 2018
Standard Chartered Bank
0
31 March 2017
Others
0
10 April 2015
State Bank Of India
0
23 August 2018
Others
0
30 March 1984
The Maharashtra State Financial Corporation
0
21 August 2017
Others
0
02 March 2002
Sicom Ltd
0
07 April 2016
Others
0
17 October 1988
State Bank Of India
0
17 October 1988
State Bank Of India
0
07 October 1988
State Bank Of India
0
02 January 1986
State Bank Of India
0
04 December 2014
State Bank Of India
0
26 September 2014
Tata Capital Financial Services Limited
0
30 May 2014
Others
0
31 May 2012
Development Credit Bank Limited
0
19 December 2012
State Bank Of India
0
22 February 2013
State Bank Of India
0
10 June 2013
State Bank Of India
0
28 February 2014
Others
0
20 December 1991
State Bank Of India
0
22 February 2013
State Bank Of India
0
07 February 2017
Tata Capital Financial Services Limited
0
27 August 1997
State Bank Of India
0
19 December 2012
State Bank Of India
0
31 March 1994
Maharashtra State Financial Corproation
0
21 October 2011
Development Credit Bank Limited
0
11 August 2017
Others
0
30 August 2023
State Bank Of India
0
14 October 2021
Standard Chartered Bank
0
06 October 2021
State Bank Of India
0
24 July 2018
Others
0
28 April 2017
Others
0
23 February 2018
Standard Chartered Bank
0
31 March 2017
Others
0
10 April 2015
State Bank Of India
0
23 August 2018
Others
0
30 March 1984
The Maharashtra State Financial Corporation
0
21 August 2017
Others
0
02 March 2002
Sicom Ltd
0
07 April 2016
Others
0
17 October 1988
State Bank Of India
0
17 October 1988
State Bank Of India
0
07 October 1988
State Bank Of India
0
02 January 1986
State Bank Of India
0
04 December 2014
State Bank Of India
0
26 September 2014
Tata Capital Financial Services Limited
0
30 May 2014
Others
0
31 May 2012
Development Credit Bank Limited
0
19 December 2012
State Bank Of India
0
22 February 2013
State Bank Of India
0
10 June 2013
State Bank Of India
0
28 February 2014
Others
0
20 December 1991
State Bank Of India
0
22 February 2013
State Bank Of India
0
07 February 2017
Tata Capital Financial Services Limited
0
27 August 1997
State Bank Of India
0
19 December 2012
State Bank Of India
0
31 March 1994
Maharashtra State Financial Corproation
0
21 October 2011
Development Credit Bank Limited
0
11 August 2017
Others
0
Documents
Letter of the charge holder stating that the amount has been satisfied-25122020
Form CHG-4-25122020_signed
CERTIFICATE OF SATISFACTION OF CHARGE-20201225
Letter of the charge holder stating that the amount has been satisfied-22122020
Form CHG-4-22122020_signed
CERTIFICATE OF SATISFACTION OF CHARGE-20201222
Form DPT-3-08122020-signed
Form PAS-6-27112020_signed
Form CHG-4-25102020_signed
Form CHG-4-24102020_signed
Letter of the charge holder stating that the amount has been satisfied-23102020
Form MR-1-20082020_signed
Copy of board resolution-20082020
Copy of shareholders resolution-20082020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -20082020
Form MR-1-19082020_signed
Copy of shareholders resolution-19082020
Copy of board resolution-19082020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -19082020
Form PAS-6-11082020_signed
Form DPT-3-04082020-signed
Form MGT-7-12122019_signed
Optional Attachment-(1)-11122019
List of share holders, debenture holders;-11122019
Copy of MGT-8-11122019
Form AOC-4(XBRL)-16112019_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-25102019
XBRL document in respect Consolidated financial statement-25102019
Form MGT-14-18102019_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-18102019
